Radiopharmaceuticals in prostate cancer - PSMA Theranostics episode 2

Episode 2 May 12, 2021 00:21:48
Radiopharmaceuticals in prostate cancer - PSMA Theranostics episode 2
COR2ED Medical Education
Radiopharmaceuticals in prostate cancer - PSMA Theranostics episode 2

May 12 2021 | 00:21:48

/

Show Notes

Dr. Tanya Dorff (City of Hope Comprehensive Cancer Center, Los Angeles, USA) and Dr. Phillip Koo (Banner MD Anderson Cancer Center, Arizona, USA) discuss the latest developments in the field of radiopharmaceuticals and their use in Prostate Cancer.

This second episode focuses on PSMA-targeted radiopharmaceuticals and how PSMA can be a target for imaging as well as for therapies. Efficacy and safety data from the phase 2 TheraP study are discussed which investigated lutetium-PSMA versus cabazitaxel in patients with mCRPC who had progressed on docetaxel. The experts also discuss the ongoing VISION trial and what the results may mean for clinical practice as well as other ongoing trials looking at lutetium-PSMA in combination with other prostate cancer therapies such as PARP inhibitors, immunotherapies, hormonal therapies and chemotherapy. Treatment sequencing is also considered in terms of where lutetium-PSMA fits into clinical practice for mCRPC patients and how the treatment compares to Radium-223.

Other Episodes

Episode 2

February 15, 2023 00:19:43
Episode Cover

PARPi and NHA combination therapy for patients with mCRPC – a US and EU perspective

COR2ED Medical Education: Dr Neal Shore, Uro-Oncologist and Chief Medical Officer for Genesis Care and Urology and Surgical Oncology in the United States and...

Listen

Episode 17

July 26, 2023 00:25:27
Episode Cover

Breast Cancer: Oral SERDs in ER+ breast cancer. Episode 2 - treatment selection and beyond

COR2ED Medical Education: In this podcast, the experts deep-dive into two patient case studies of ER+/HER2- metastatic breast cancer, discussing the intricacies of treatment...

Listen

Episode

November 29, 2023 00:27:39
Episode Cover

Gene therapy and gene-modified cell therapy in rare diseases

Gene therapy and gene-modified cell therapies have a great potential for rare diseases to either help patients to cure their disease or improve their...

Listen